Hematologic Malignancy
Mature B-Cell Neoplasm
CI-CAN-00003258Explore in graph →
HematologicNon-malignant1,787 active trials44 approved drugs119 evidence items
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00003258Explore in graph →
Clinical trials
6,664 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02903381 | A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma | completed | Phase 2 | 8 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 13, 2023 | clinicaltrials |
| NCT02279394 | E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma | completed | Phase 2 | 51 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 9, 2023 | clinicaltrials |
| NCT00224393 | Phase II Trial of Enbrel in Patients With Primary Systemic Amyloidosis | completed | Phase 2 | 60 | The Cleveland ClinicOTHER | 0 | May 30, 2023 | clinicaltrials |
| NCT01264315 | Safety And Efficacy Of Lenalidomide As Maintenance Therapy In Patients With Newly Diagnosed Multiple Myeloma Following A Tandem Autologous-Allogeneic Transplant | completed | Phase 2 | 53 | Fondazione EMN Italy OnlusOTHER | 1 | May 26, 2023 | clinicaltrials |
| NCT00602459 | Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia | completed | Phase 2 | 418 | National Cancer Institute (NCI)NIH | 2 | May 22, 2023 | clinicaltrials |
| NCT02416206 | High Dose Chemotherapy Using BeEAM for Autologous Transplant in Multiple Myeloma | completed | Phase 2 | 65 | Northside Hospital, Inc.OTHER | 1 | May 18, 2023 | clinicaltrials |
| NCT02751255 | Daratumumab in Combination With ATRA(DARA/ATRA) | completed | Phase 1 / Phase 2 | 60 | Amsterdam UMC, location VUmcOTHER | 1 | Apr 28, 2023 | clinicaltrials |
| NCT01092182 | Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma | completed | Phase 2 | 194 | National Cancer Institute (NCI)NIH | 1 | Apr 27, 2023 | clinicaltrials |
| NCT02581007 | Reduced Intensity Conditioning Transplant Using Haploidentical Donors | completed | Phase 2 | 25 | Northside Hospital, Inc.OTHER | 1 | Apr 27, 2023 | clinicaltrials |
| NCT01794520 | Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 117 | AbbVieINDUSTRY | 4 | Apr 10, 2023 | clinicaltrials |
| NCT01040026 | Expanded Natural Killer (NK) Cells for Multiple Myeloma Study | completed | Phase 1 / Phase 2 | 10 | University Hospital, Basel, SwitzerlandOTHER | 1 | Apr 4, 2023 | clinicaltrials |
| NCT03238599 | Pedometer Activity Monitoring After ASCT(PAMAL) | completed | Phase 2 | 62 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Apr 3, 2023 | clinicaltrials |
| NCT00783367 | Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas | completed | Phase 2 | 50 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 30, 2023 | clinicaltrials |
| NCT01238692 | A Phase II Study of Oral Panobinostat (LBH589) and Rituximab to Treat Diffuse Large B Cell Lymphoma (DLBCL) | completed | Phase 2 | 42 | Sarit AssoulineOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT01168921 | Phase II Eltrombopag in Chronic Lymphocytic Leukemia (CLL) | completed | Phase 2 | 23 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 23, 2023 | clinicaltrials |
| NCT02840539 | Trial of Bortezomib, Cytarabine, and Dexamethasone in Mantle Cell Lymphoma(BATMAN) | completed | Phase 2 | 19 | Seoul National University HospitalOTHER | 1 | Mar 20, 2023 | clinicaltrials |
| NCT04323657 | TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia | completed | Phase 1 / Phase 2 | 6 | TCR2 TherapeuticsINDUSTRY | 1 | Mar 16, 2023 | clinicaltrials |
| NCT00644189 | Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 50 | Massachusetts General HospitalOTHER | 1 | Mar 15, 2023 | clinicaltrials |
| NCT03312530 | A Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 49 | Hoffmann-La RocheINDUSTRY | 9 | Feb 28, 2023 | clinicaltrials |
| NCT05338047 | Efficacy of Generic Pegfilgrastim vs Brand Name Pegfilrastim for Neutrophil Recovery After Autotransplant | completed | Phase 2 | 30 | Hospital Universitario Dr. Jose E. GonzalezOTHER | 1 | Feb 28, 2023 | clinicaltrials |
| NCT03439280 | A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM) | completed | Phase 1 / Phase 2 | 50 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Feb 24, 2023 | clinicaltrials |
| NCT01066663 | Pyrimethamine for the Treatment of Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | completed | Phase 1 / Phase 2 | 20 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 22, 2023 | clinicaltrials |
| NCT03019640 | Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma | completed | Phase 2 | 22 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT02853370 | Bendamustine and Rituximab for the Treatment of Splenic Marginal Zone Lymphoma | completed | Phase 2 | 78 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 2 | Feb 1, 2023 | clinicaltrials |
| NCT00005780 | Chemotherapy Plus Vaccination to Treat Mantle Cell Lymphoma | completed | Phase 2 | 26 | National Cancer Institute (NCI)NIH | 1 | Jan 31, 2023 | clinicaltrials |
| NCT04030195 | Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL | completed | Phase 1 / Phase 2 | 18 | Precision BioSciences, Inc.INDUSTRY | 1 | Jan 31, 2023 | clinicaltrials |
| NCT02336815 | Selinexor Treatment of Refractory Myeloma(STORM) | completed | Phase 2 | 202 | Karyopharm Therapeutics IncINDUSTRY | 6 | Jan 26, 2023 | clinicaltrials |
| NCT02593123 | Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis | completed | Phase 2 | 31 | Virginia Commonwealth UniversityOTHER | 1 | Jan 23, 2023 | clinicaltrials |
| NCT03276468 | Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas | completed | Phase 2 | 136 | The Lymphoma Academic Research OrganisationOTHER | 1 | Jan 10, 2023 | clinicaltrials |
| NCT00849147 | Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603) | completed | Phase 2 | 55 | Medical College of WisconsinOTHER | 1 | Jan 4, 2023 | clinicaltrials |
| NCT02186834 | Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 28 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 4, 2023 | clinicaltrials |
| NCT02440464 | Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302) | completed | Phase 2 | 57 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Jan 4, 2023 | clinicaltrials |
| NCT00864227 | Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant (BMT CTN 0604) | completed | Phase 2 | 54 | Medical College of WisconsinOTHER | 1 | Dec 14, 2022 | clinicaltrials |
| NCT03877055 | A Study of Copanlisib and Ibrutinib in Mantle Cell Lymphoma | completed | Phase 1 / Phase 2 | 8 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 14, 2022 | clinicaltrials |
| NCT01177397 | Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma | completed | Phase 1 / Phase 2 | 226 | CelgeneINDUSTRY | 4 | Dec 13, 2022 | clinicaltrials |
| NCT02604511 | Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing | completed | Phase 2 | 31 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 7, 2022 | clinicaltrials |
| NCT02802943 | iVAC-CLL01: Patient-individualized Peptide Vaccination After First Line Therapy of CLL | completed | Phase 2 | 56 | University Hospital TuebingenOTHER | 1 | Nov 28, 2022 | clinicaltrials |
| NCT03187262 | A Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia | completed | Phase 2 | 13 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 23, 2022 | clinicaltrials |
| NCT02963493 | A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma(HORIZON) | completed | Phase 2 | 157 | Oncopeptides ABINDUSTRY | 4 | Nov 22, 2022 | clinicaltrials |
| NCT01647971 | Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 39 | TG Therapeutics, Inc.INDUSTRY | 1 | Nov 21, 2022 | clinicaltrials |
| NCT03200015 | Rituximab, Cyclophosphamide, Vincristine and Prednisone (R-CHOP) Plus Metformin in Diffuse Large-B-cell Lymphoma | completed | Phase 2 | 15 | Hospital Universitario Dr. Jose E. GonzalezOTHER | 1 | Nov 7, 2022 | clinicaltrials |
| NCT02780609 | Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma | completed | Phase 1 / Phase 2 | 22 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 4, 2022 | clinicaltrials |
| NCT02556931 | Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies | completed | Phase 2 | 117 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Nov 3, 2022 | clinicaltrials |
| NCT02654132 | An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3) | completed | Phase 2 | 117 | Bristol-Myers SquibbINDUSTRY | 11 | Nov 1, 2022 | clinicaltrials |
| NCT02722941 | Panobinostat (LBH589): Multiple Myeloma - Autologous Hematopoietic Cell Transplantation (HCT) | completed | Phase 2 | 30 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 1, 2022 | clinicaltrials |
| NCT02660710 | Rituximab Plus CHOP Chemotherapy for Diffuse Large B-cell Lymphoma | completed | Phase 2 | 39 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Oct 28, 2022 | clinicaltrials |
| NCT01842672 | Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia(MITCL) | completed | Phase 1 / Phase 2 | 41 | New York Medical CollegeOTHER | 1 | Oct 25, 2022 | clinicaltrials |
| NCT01859819 | Treatment for Advanced B-Cell Lymphoma(REBOOT) | completed | Phase 2 | 45 | New York Medical CollegeOTHER | 1 | Oct 25, 2022 | clinicaltrials |
| NCT02013128 | Ublituximab + Ibrutinib in Select B-cell Malignancies | completed | Phase 1 / Phase 2 | 66 | TG Therapeutics, Inc.INDUSTRY | 1 | Oct 24, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Jun 13, 2023source: clinicaltrials